| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Virax Biolabs Group Limited Ordinary Shares$0.15
0 (-1.84%)
Market Cap
772.78 K
EPS
-1.25
P/E Ratio
-0.08 $
Value Trade
5.43 M
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
490.44 K
52 Week Range
0.10 - 1.20
% held by Insiders
1.79 %
% held by Institutions
4.62 %
Enterprise Value
-2.27 M
Total Shares
7.43 M
Short %
15.23 %
Float Shares
7.02 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in VRAX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Virax Biolabs Group Limited Ordinary Shares (VRAX) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
VRAX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
VRAX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
VRAX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
VRAX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
VRAX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-VRAX
May 26, 2026Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune™ in Long COVID and Related Post-Acute Infection Syndromes
Virax Biolabs has reported positive early pilot data for its ViraxImmune™ test, designed for Long COVID and related syndromes. The test demonstrated 88% specificity and 92% positive predictive value in distinguishing patients from healthy controls. The company is preparing for a larger clinical validation involving 300 participants, with results expected in early 2027. This development could significantly enhance diagnostic strategies in an area with considerable unmet needs.
Read more →-VRAX
May 22, 2026filed as part of the Form 6-K report containing the Notice of Meeting and Proxy Statement in substitution for, and to the exclusion of, the existing amended and restated memorandum and articles of association of the Comp
Virax Biolabs Group Limited has scheduled an Extraordinary General Meeting for June 5, 2026, where shareholders will vote on several proposals, including a share consolidation. The Board of Directors encourages shareholders to participate, either in person or virtually. Shareholders of record by May 18, 2026, are entitled to vote, and methods for proxy voting have been provided. The meeting aims to foster shareholder engagement and streamline operations through the proposed consolidation of shares.
Read more →-VRAX
Apr 14, 2026Virax Biolabs' CEO James Foster Outlines Strategic Priorities and Near-Term Milestones in Letter to Shareholders Virax Biolabs is advancing a focused strategy centered on ViraxImmune and a U.S. market-entry pathway, whic
Virax Biolabs' CEO James Foster detailed the company's strategic priorities and upcoming milestones in a recent letter to shareholders. Focused on the development of ViraxImmune, the company aims to target post-acute infection syndromes, which are currently underdiagnosed. With a strong balance sheet and no debt, Virax is advancing towards U.S. market entry through a Laboratory Developed Test pathway. Upcoming milestones over the next few months include important data readouts that may validate their assay and inform future commercialization efforts.
Read more →-VRAX
Jan 30, 2026filed as part of the Form 6-K. Administration . The 2026 Plan will be administered by the Compensation Committee. The Committee may delegate any or all of the authority of the Committee with respect to Awards to Grantees
Virax Biolabs Group Limited is set to hold its Annual General Meeting (AGM) on March 11, 2026, at BioCity Glasgow. The meeting will address various proposals, including the adoption of the 2026 Equity Incentive Plan and the re-appointment of directors. Shareholders eligible to vote must hold shares as of January 12, 2026, and are encouraged to submit proxies if unable to attend. Clear voting procedures are outlined to facilitate shareholder participation.
Read more →-VRAX
Dec 3, 2025Virax Biolabs Group Limited Announces $5 Million Private Placement LONDON
Virax Biolabs Group Limited has announced a successful private placement, securing $5 million by selling 12.5 million ordinary shares at a price of $0.40 each. The proceeds will be utilized for working capital and other corporate uses. The closing of the private placement is anticipated on December 4, 2025, pending customary conditions. H.C. Wainwright & Co. will act as the exclusive placement agent for this transaction, which involves preferred investment options with an exercise price of $0.40. Virax continues to focus on immunology and diagnostic innovations.
Read more →-VRAX
Dec 2, 2025Unaudited Condensed Consolidated Interim Financial Statements as of
VIRAX Biolabs Group Limited released its unaudited interim financial statements for the six months ending September 30, 2025. The results show a net loss of $2.34 million, with total assets of $5.71 million. While the company is developing its ViraxImmune assay to detect immune responses to various conditions, it faces challenges, including a high operating loss and decreased cash flow. Liabilities have significantly reduced, but the company still shows concerns with its current asset position.
Read more →-VRAX
Mar 18, 2025Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes LONDON
Virax Biolabs has initiated patient enrollment for a multi-center clinical study in the UK that aims to evaluate T cell dysfunction in post-acute infection syndromes, including long COVID and other conditions. The study, conducted in partnership with the NHS, will involve up to 200 participants, with results expected by Q2 2026. This research seeks to address the lack of reliable diagnostics for these syndromes and improve patient care through enhanced immune health assessments.
Read more →-VRAX
Mar 13, 2025Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19 th World Immune Regulation Meeting LONDON, 
Virax Biolabs Group Limited presented significant data on T-Cell dysfunction associated with post-acute infection syndromes at the World Immune Regulation Meeting in Davos. The data suggests that chronic infections lead to progressive T-Cell exhaustion, which could impair immune response. The company plans to conduct clinical validation studies to explore the relationship between T-Cell dysfunction and various chronic conditions like long COVID and chronic fatigue. This research is aimed at enhancing diagnostic capabilities to better manage post-viral syndromes.
Read more →-VRAX
Mar 5, 2025Virax Biolabs to Present at 19th World Immune Regulation Meeting
Virax Biolabs Group Limited will present its work on T cell dysfunction in post-acute infection syndromes at the upcoming 19th World Immune Regulation Meeting in Davos, Switzerland, taking place from March 12-15, 2025. Dr. Nigel McCracken, the Chief Operating Officer, will lead the presentation. The event is expected to host around 600 scientists and clinicians discussing advancements in immunology, and Virax will also showcase their immune profiling products at a designated booth.
Read more →-VRAX
Feb 25, 2025Virax Biolabs Believes Technology Aligns with United States Department of Health and Human Services' Transparency Priority on Vaccine Efficacy Company Positioned to Support Public Health through Vaccine Efficacy Testing
Virax Biolabs Group Limited has expressed its belief that its technology is in alignment with the U.S. Department of Health and Human Services' push for transparency regarding vaccine efficacy. The company aims to support public health by providing tools for measuring vaccine effectiveness and monitoring immune profiles. Additionally, Virax is focused on advancing research related to protective immunity and T cell dysfunction, emphasizing its commitment to empowering individuals in their health decisions. CEO James Foster highlighted the company's readiness to contribute to vaccine efficacy testing as part of broader public health initiatives.
Read more →-VRAX
Dec 17, 2024Virax Biolabs' CEO James Foster Issues Letter to Shareholders LONDON
Virax Biolabs' CEO James Foster has communicated the company's plans for 2025 in a letter to shareholders. Key achievements in 2024 include the launch of the ImmuneSelect portfolio and the initiation of a clinical study assessing the ViraxImmune IVD platform in post-acute infection syndrome patients. The company is focused on expanding distribution partnerships and preparing for U.S. regulatory submissions. Financially, Virax has reported a robust cash position with no long-term debt, aiming for significant advancements in immune diagnostic solutions in the coming year.
Read more →-VRAX
Dec 10, 2024Virax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect Across the European Union, Norway, and Switzerland LONDON
Virax Biolabs Group Limited announced a non-exclusive distribution agreement with Tebubio to expand the availability of its ImmuneSelect Research Use portfolio across the European Union, Norway, and Switzerland. This collaboration aims to enhance the distribution of diagnostic tools focused on immune responses to viral diseases. CEO James Foster emphasized the importance of this agreement in increasing accessibility for life science institutions in Europe. The ImmuneSelect portfolio includes products designed for researching adaptive immunity and is compatible with standard laboratory equipment.
Read more →-VRAX
Oct 31, 2024filed as part of the Form 6-K. Administration . The 2024 Plan will be administered by the Compensation Committee. The Committee may delegate any or all of the authority of the Committee with respect to Awards to Grantees
Virax Biolabs Group Limited is set to hold its Annual General Meeting (AGM) on December 12, 2024, at BioCity Glasgow. The meeting will allow shareholders to vote on key proposals, including the re-election of directors and the approval of the 2024 Equity Incentive Plan. Eligible shareholders can participate in person or online, ensuring broad engagement with the company's leadership. The board of directors urges all shareholders to vote, highlighting the importance of their participation.
Read more →-VRAX
Oct 23, 2024Virax Biolabs Announces Distribution Agreement with Europa Biosite to Commercialize ImmuneSelect in the United Kingdom and Ireland LONDON
Virax Biolabs has entered into a distribution agreement with Europa Biosite to commercialize its ImmuneSelect Research Use portfolio in the United Kingdom and Ireland. This partnership aims to enhance the accessibility of ImmuneSelect products, which are crucial for assessing adaptive immunity, to researchers and pharmaceutical companies. Europa Biosite's established distribution infrastructure in Europe is expected to facilitate quick delivery and support for these products. ImmuneSelect includes various offerings for investigating immune responses against several pathogens, including SARS-CoV-2 and Lyme Disease.
Read more →-VRAX
Aug 21, 2024Virax Biolabs Group Limited Announces $5 Million Registered Direct Offering of Ordinary Shares LONDON
Virax Biolabs Group Limited has announced a $5 million registered direct offering of its ordinary shares at a price of $4.50 each. The offering is expected to close by August 23, 2024, pending customary conditions. Proceeds from this offering will be utilized for working capital and general corporate purposes. The announcement details the terms of the issuance and stresses the forward-looking nature of the company's statements regarding future performance.
Read more →-VRAX
Apr 25, 2024Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024 LONDON
Virax Biolabs has launched ImmuneSelect, an immune profiling portfolio designed to evaluate adaptive immunity and aid in understanding post-viral syndromes. This launch occurs during the ESCMID Global 2024 congress and signifies an important step towards commercializing Virax's T-cell diagnostic platform. ImmuneSelect is dedicated to investigating T-cell driven immunity related to conditions such as Long COVID. The solutions, including peptide pools for various pathogens, are available for research use only and aim to provide new tools for immune response diagnostics.
Read more →-VRAX
Apr 16, 2024Virax Biolabs Group Limited to Participate at ESCMID Global 2024 LONDON
Virax Biolabs Group Limited will host a booth at the ESCMID Global 2024 from April 27 to April 30 in Barcelona, Spain. This event is a major platform for the discussion of infectious diseases, attracting over 20,000 attendees, including leading experts and industry leaders. The company will present its research products and engage with potential customers. Virax is particularly focused on developing T-Cell-based technologies aimed at diagnosing viral diseases and addressing post-viral syndromes like Long COVID.
Read more →-VRAX
Mar 15, 2024Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency LONDON
Virax Biolabs Group Limited has received a notification from NASDAQ indicating that it does not comply with the minimum bid price requirement of $1.00 per share. The company has a compliance period of 180 days to rectify this issue, or it risks potential delisting. Despite this challenge, the company continues to operate and trade on NASDAQ under the symbol VRAX. Virax is also engaged in the development of innovative diagnostic technologies, which may bolster its business prospects going forward.
Read more →-VRAX
Dec 21, 2023Virax Biolabs Forges Strategic Research Collaboration with University of Manchester and the Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in COVID Patients LONDON
Virax Biolabs announced a strategic research collaboration with the University of Manchester and the Northern Care Alliance Foundation Trust to improve understanding of T-Cell immune responses in COVID patients. The partnership aims to utilize the ViraxImmune IVD platform in the ImRESP study, targeting both respiratory disease patients and those with Long COVID symptoms. The research will assess T-cell profiles to aid in developing diagnostic tests for managing Long COVID. This initiative reflects Virax's dedication to enhancing diagnostic capabilities in post-viral syndromes and chronic inflammation conditions.
Read more →-VRAX
Dec 20, 2023Companies Act (Revised) Company Limited by Shares Virax Biolabs Group Limited THIRD AMENDED AND RESTATED memorandum of association (adopted by special resolution passed on 6 December 2023 and effective on 18 December 202
Virax Biolabs Group Limited has adopted a Third Amended and Restated Memorandum of Association, effective December 18, 2023, following a special resolution passed on December 6, 2023. This document outlines the company’s operational capacity and corporate governance structure, allowing for unrestricted business activities unless otherwise licensed. The amended articles further clarify the procedures and powers related to share capital, member meetings, and director appointments.
Read more →-VRAX
Dec 14, 2023Virax Biolabs Group Limited Announces 1-for-10 Share Consolidation LONDON
Virax Biolabs Group Limited has announced a 1-for-10 share consolidation after receiving approval from shareholders on December 6, 2023. This move is intended to help the company comply with Nasdaq Marketplace requirements, enabling its shares to remain listed. The consolidation will take effect on December 18, 2023, and will not impact the percentage interests of shareholders, although fractional shares will be rounded up. The company aims to enhance its investment appeal while navigating the challenges imposed by market conditions.
Read more →-VRAX
Nov 8, 2023filed as part of the Form 6-K. Administration . The Plan will be administered by the Compensation Committee. The Committee may delegate any or all of the authority of the Committee with respect to Awards to Grantees othe
Virax Biolabs Group Limited has announced its 2023 Annual General Meeting scheduled for December 6, 2023, in Glasgow. The Meeting will address multiple proposals, with the board recommending a vote in favor of all items. Shareholders eligible to vote must be on record by October 9, 2023, and they have various methods to submit their votes, including online and by mail.
Read more →-VRAX
Oct 31, 2023E xhibit 99.1 Virax Biolabs Group Limited ( the Company ) CLAWBACK POLICY Introduction The Board of Directors of the Company (the Board ) believes that it is in the best interests of the Company and its shareholders to c
Virax Biolabs Group Limited has adopted a new clawback policy that aims to ensure accountability among its executive officers. This policy outlines the conditions under which the company can recoup executive compensation in the event of an accounting restatement due to material noncompliance with financial reporting requirements. It applies to current and former executives, emphasizing the importance of maintaining integrity and aligning compensation with performance. The policy will be administered by the Board or the Compensation Committee, and can be amended as needed to comply with applicable regulations.
Read more →-VRAX
Sep 12, 2023Virax Biolabs Group Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts Webinar LONDON, United Kingdom
Virax Biolabs Group has launched an early-access program for its proprietary ViraxImmune T-cell-based test, aimed at researchers assessing immune responses to SARS-Cov-2. This test combines ELISpot assays with specific peptides to evaluate memory T-cell activation and provides a detailed immune profile. A webinar is scheduled for September 20, 2023, to discuss the program further. The company anticipates the demand for T-cell tests to increase due to their potential benefits over conventional testing methods.
Read more →-VRAX
Sep 1, 2023Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth Momentum LONDON, United Kingdom
Virax Biolabs Group has appointed Dr. Nigel McCracken as Chief Operating Officer, succeeding Mr. Cameron Shaw, who will join the Advisory Board. Dr. McCracken, who has extensive experience in diagnostics and operations, will oversee the company's growth strategies, including the anticipated launch of ViraxImmune. Additionally, Mark Ternouth will join the Board of Directors, bringing further expertise to the executive team. This leadership expansion is aimed at enhancing Virax's capabilities in delivering innovative diagnostic tools for viral diseases.
Read more →-VRAX
Aug 3, 2023Nasdaq Approves 180-Day Extension for Virax Biolabs Group to Meet Minimum $1 Bid LONDON
Virax Biolabs Group Limited has received a 180-day extension from Nasdaq to meet the minimum bid price requirement of $1 per share. This extension allows the company until January 29, 2024, to regain compliance, following a prior notice that indicated non-compliance due to share price performance. Virax, an innovative diagnostics firm, focuses on viral disease detection and is developing proprietary T-Cell Test technology aimed at assessing immune responses. The company aims to address various viral threats, including COVID-19 and others.
Read more →-VRAX
Jul 18, 2023Virax Biolabs Group Continues Growth and Expansion with the Addition of Research and Laboratory Facilities LONDON, United Kingdom and DUBAI, United Arab Emirates
Virax Biolabs Group is expanding its operations with the addition of two new research and laboratory facilities in the United Kingdom. These state-of-the-art facilities, located in London and Glasgow, will enhance the company's capabilities in developing its ViraxImmune platform. The laboratories are strategically positioned near top institutions and provide access to essential resources for research and collaboration. The expansion marks a significant milestone for Virax in its mission to provide advanced healthcare solutions.
Read more →-VRAX
Jun 14, 2023Virax Biolabs' CEO James Foster Issues Letter to Shareholders LONDON, United Kingdom, and DUBAI, United Arab Emirates
Virax Biolabs' CEO James Foster provided a mid-year update to shareholders, focusing on the anticipated launch of the ViraxImmune platform, which will allow individuals to manage their immune health proactively. The platform utilizes T-Cell response testing and provides results through a mobile application. While approvals from regulatory bodies are necessary for commercialization, the company expects to have initial product availability for research use only by late 2023, with broader market access targeted for 2024. Additionally, Virax is expanding its distribution partnerships and infrastructure to enhance its global reach.
Read more →-VRAX
May 4, 2023Virax Biolabs Group Announces Establishment of Regional Headquarters at Dubai Science Park LONDON, and DUBAI, United Arab Emirates: MAY 4, 2023 /PRNewswire/-- Virax Biolabs Group Limited (“Virax” or the &#x
Virax Biolabs Group Limited has established a regional headquarters at Dubai Science Park, aiming to enhance its operations and expansion into the Middle East. This move will facilitate the distribution of in-vitro diagnostics and proprietary T-Cell tests. The new headquarters is expected to foster local partnerships, create jobs, and contribute to the UAE's healthcare ecosystem while aligning with the Dubai Economic Agenda D33. The location is part of a vibrant science community that supports innovation and sustainable growth in various sectors.
Read more →-VRAX
Apr 19, 2023Virax Biolabs Group Limited Has Entered into an Agreement for the Distribution of Marburg Virus PCR Testing Kits LONDON, April 19 2023 – Virax Biolabs Group Limited (“Virax” or the “Company&#x
Virax Biolabs Group Limited has announced an agreement to distribute Marburg Virus PCR testing kits, utilizing real-time PCR technology for RNA detection. This product aims to address the significant public health need for accurate testing of the highly virulent Marburg Virus. CEO James Foster emphasized the company’s commitment to improving global health through advanced diagnostic tools. The testing kits are intended for launch in regions that accept CE marking, underlining their importance in managing infectious disease outbreaks.
Read more →-VRAX
Mar 8, 2023Virax Biolabs Group Limited Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules LONDON
Virax Biolabs Group Limited announced the completion of a $4 million private placement of ordinary shares and preferred investment options under Nasdaq rules. The funding is directed towards advancing their proprietary T-Cell Test technology aimed at viral disease diagnostics. The transaction is expected to close on or about March 10, 2023, pending customary conditions. Additionally, associated securities have not been registered under the Securities Act, limiting their future resale potential.
Read more →-VRAX
Mar 7, 2023Virax Biolabs Group Limited Introduces Avian Influenza A Virus Real-Time PCR Test Kit LONDON
Virax Biolabs Group Limited has launched an Avian Influenza A Virus real-time PCR test kit aimed at detecting various strains including H5N1. The kit is intended for use in laboratory settings and provides critical capabilities for healthcare professionals in identifying AIV infections. This initiative is part of Virax's strategy to expand its distribution of diagnostic solutions for viral threats in the European market. The company anticipates this test will enhance rapid interventions in high-risk environments.
Read more →-VRAX
Feb 7, 2023Virax Biolabs Group Limited Announces Purchase Order to Launch COVID-19 and Influenza A+B Antigen Combo Rapid Tests with Cosmos Health (NASDAQ:COSM) LONDON
Virax Biolabs Group Limited has announced a purchase order to launch a COVID-19 and Influenza A+B Antigen Combo Rapid Detection Kit in collaboration with Cosmos Health. This partnership grants Cosmos exclusive distribution rights in Greece and Cyprus and the option for wider distribution across Europe. The rapid test aims to enhance early detection of these viral infections, which are significant global health concerns. The test is designed to deliver results quickly, within 15 minutes, emphasizing the importance of timely diagnosis in improving health outcomes.
Read more →-VRAX
Feb 2, 2023Unaudited Condensed Interim Financial Statements as of
Virax Biolabs Group Limited reported its unaudited condensed interim financial statements for the six months ending September 30, 2022. The company experienced a substantial net loss of $1,443,611, which represents a notable decline compared to the previous year's loss. Operating expenses exceeded revenue significantly, resulting in a gross profit of only $118. Additionally, the company has raised its total liabilities and stockholders' equity deficit, signaling ongoing financial challenges.
Read more →-VRAX
Jan 4, 2023Virax Biolabs Introduces Human Papillomavirus (“HPV”) Test Kit Kit Available Now for Distribution LONDON
Virax Biolabs has launched a new Human Papillomavirus (HPV) test kit designed to cover 18 different genotypes, including the high-risk type 53. The company plans to begin distribution in the first quarter of 2023 to markets that accept the CE mark, particularly in the European Union. CEO James Foster expressed optimism about capturing market share, citing advantages such as shorter processing times and lower costs compared to existing HPV tests. HPV remains a significant public health concern, responsible for a high number of cervical cancer cases globally.
Read more →-VRAX
Dec 6, 2022COVID-19 Rapid Antigen Test Distributed By Virax Biolabs Receives Emergency Use Authorization in the United States Kits available Now for Distribution LONDON
COVID-19 Rapid Antigen Test Distributed By Virax Biolabs Receives Emergency Use Authorization in the United States Kits available Now for Distribution LONDON, Dec. 6, 2022 /PRNewswire/ -- Virax Biolabs Group Limited ( Virax or the Company ) (Nasdaq: VRAX), an innovative biotech
Read more →-VRAX
Nov 15, 2022Virax Biolabs Appoints Richard Pallin as the Vice President of In Vitro Diagnostic Sales LONDON
Virax Biolabs Appoints Richard Pallin as the Vice President of In Vitro Diagnostic Sales LONDON, Nov. 15, 2022 /PRNewswire/ -- Virax Biolabs ( Virax or the Company ) (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral
Read more →-VRAX
Nov 4, 2022Virax Biolabs Group Limited Announces $3.8 Million Private Placement LONDON
Virax Biolabs Group Limited Announces $3.8 Million Private Placement LONDON, Nov. 4, 2022/PRNewswire/-- Virax Biolabs Group Limited ( Virax or the Company ) (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases,
Read more →-VRAX
Nov 3, 2022Virax Biolabs Introduces RSV-Influenza-COVID Triple Virus Antigen Rapid Test Kit Kits available in November for Distribution LONDON
Virax Biolabs Introduces RSV-Influenza-COVID Triple Virus Antigen Rapid Test Kit Kits available in November for Distribution LONDON, Nov. 3, 2022 /PRNewswire/ -- Virax Biolabs ( Virax or the Company ) (Nasdaq: VRAX), an innovative Biotechnology company focused on the prevention
Read more →-VRAX
Oct 26, 2022Virax Biolabs Group Limited Announces Initiation of its Virax Immune COVID-19 Analytical Performance Study LONDON
Virax Biolabs Group Limited Announces Initiation of its Virax Immune COVID-19 Analytical Performance Study LONDON, Oct. 26, 2022/PRNewswire/-- Virax Biolabs Group Limited ( Virax or the Company ) (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of imm
Read more →-VRAX
Sep 22, 2022Virax Biolabs Group Limited Announces Distribution Agreement to Market Monkeypox Virus Real-Time PCR Detection Kit with Cosmos Holdings Inc. • Exclusive distribution agreement signed with Cosmos Holdings Inc. (Nas
Virax Biolabs Group Limited Announces Distribution Agreement to Market Monkeypox Virus Real-Time PCR Detection Kit with Cosmos Holdings Inc. -Exclusive distribution agreement signed with Cosmos Holdings Inc. (Nasdaq: COSM), providing for exclusive distribution rights in Greece a
Read more →-VRAX
Sep 20, 2022Virax Biolabs Introduces Monkeypox Virus Antigen Rapid Test Kit Kits available in September for Distribution LONDON
Virax Biolabs Introduces Monkeypox Virus Antigen Rapid Test Kit Kits available in September for Distribution LONDON, Sep. 20, 2022 /PRNewswire/ -- Virax Biolabs ( Virax or the Company ) (Nasdaq: VRAX), an innovative diagnostics company focused on the prevention, detection, and
Read more →-VRAX
Sep 12, 2022Virax BioLabs Presents at H.C. Wainwright's 24th Annual Global Investment Conference LONDON
Virax BioLabs Presents at H.C. Wainwright's 24th Annual Global Investment Conference LONDON, Sep. 12, 2022 /PRNewswire/ -- Virax Biolabs ( Virax or the Company ) (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral dise
Read more →-VRAX
Sep 6, 2022Virax BioLabs to Present at H.C. Wainwright's 24th Annual Global Investment Conference in New York
Virax BioLabs to Present at H.C. Wainwright's 24th Annual Global Investment Conference in New York, NY LONDON, Sep. 6, 2022 /PRNewswire/ -- Virax Biolabs ( Virax or the Company ) (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagno
Read more →-VRAX
Jul 26, 2022CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF VIRAX BIOLABS GROUP LIMITED (Conditionally adopted by a board resolution dated
CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF VIRAX BIOLABS GROUP LIMITED (Conditionally adopted by a board resolution dated January 21, 2022 with effect from the effective date of the registration statement of the Company) The purpose of the Audit Committee of
Read more →Competitive Position
How VRAX ranks across every disease it competes inCompetitive Position is a premium feature
See how VRAX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial